BACKGROUND Large cohort studies provide conflicting evidence regarding the potential for oral macrolide antibiotics
respectively (3, 4) . However, other studies failed to detect a significant relationship between macrolides and CV risk (5, 6) . These inconsistencies among studies could be partly explained by different types of macrolide antibiotics, study designs, population characteristics, and different baseline levels of CV risk and/or disease outcomes. Furthermore, cardiovascular risk may be underestimated due to lack of distinction between former and current macrolide use.
Given this background, the cardiac safety profiles of individual macrolides need to be better elucidated to help guide clinical treatment decisions. Therefore, we conducted a meta-analysis to examine the link between macrolides and CV risk, including SCD or ventricular tachyarrhythmias (VTA), cardiovascular death, death from any cause, myocardial infarction (MI), stroke, and any cardiovascular events.
METHODS
We searched MEDLINE (source, PubMed; January 1, 1966 , to April 30, 2015) and EMBASE (January 1, 1980, to April 30, 2015) using the following text and key words in combination, both as MeSH terms and text words: macrolides, azithromycin, erythromycin, clarithromycin, roxithromycin, cardiac, cardiovascular, death, mortality, ventricular tachycardia, ventricular arrhythmia, torsades de pointes, sudden cardiac death, and cardiac arrest. We searched articles published in any language and scrutinized references from these studies to identify other relevant studies.
To minimize differences, studies were required: 1) to contain the minimum information necessary to estimate the relative risk (RR) associated with macrolides and a corresponding measure of uncertainty (i.e., 95% confidence interval [CI] , SE, variance, or p value); 2) to be cohort studies, case-control studies, or randomized controlled trials (RCTs) published as original articles (case reports and prevalence studies were excluded); and 3) to be independent. In case of multiple publications/reports on the same population or subpopulation, we considered the estimates from the most recent or informative reports.
Three authors (Y-J.C., X-M.C., and X-Y.N.) independently extracted the data, which included the first author's name, publication year, geographical location, sex, mean age, study size, study design, sampling framework, study population, number of CV events, categories of macrolides, covariates adjusted for in the multivariable analysis, and relative risks and associated measures of variance for all categories of macrolides. Primary authors were contacted if the study did not report data amenable to the creation of 2 Â 2 tables. We used the Newcastle-Ottawa quality assessment scale (7) to evaluate the quality of cohort and case-control studies and modified Jadad score (8) to evaluate the quality of RCTs. We developed the evaluation criteria with score ranges from 0 to 9 points for cohort and case-control studies and 0 to 7 points for RCTs, with a higher score indicating higher study quality.
The primary study endpoint was SCD or VTA, as defined by International Classification of Diseases10th revision codes as ventricular tachycardia, torsades de pointes, ventricular fibrillation, ventricular flutter, sudden cardiac arrest, and SCD. The secondary endpoint was CV death, because we hypothesized that the incidence of cardiac death should be increased if macrolides were pro-arrhythmic. Additionally, we included an analysis of death from any cause to examine whether the risk for cardiac death would be offset by the survival benefit of anti-infection by macrolides. We also analyzed MI and any CV events that might precipitate SCD or VTA.
STATISTICAL ANALYSIS. RR was used as a measurement of the association between macrolides and cardiovascular risk. For case-control studies, the odds ratio (OR) was used as estimates of the RR because CV events are sufficiently rare (9) .
When RR were available, we used the most comprehensively adjusted risk estimates reported in the original manuscript. When the actual RR was not available, we calculated RRs and 95% CIs by using Stata version 11.0 software (used for all analyses; StataCorp LP, College Station, Texas). For studies that had endpoints with zero events in a treatment arm, RRs and 95% CI values were calculated using a 0.5 cell correction (10) . We used random rather than fixed effects models to estimate pooled RRs to account for heterogeneity, however small, of the risk estimates and, therefore, to be more conservative. Pooled RRs were expressed with 95% CIs. We calculated the I 2 (95% CI) statistic to assess heterogeneity across studies, applying the following interpretation for I 2 <50%, low heterogeneity; 50% to 75%, moderate heterogeneity; >75%, high heterogeneity (11, 12) .
Subgroup analyses and metaregression models were carried out to investigate potential sources of between-study heterogeneity. We calculated absolute 
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of events among patients not taking macrolides.
On the basis of population-based cohort studies, I 0 was estimated by weighting the sample size of each study (4) . Small study bias, consistent with publication bias, was assessed with funnel plot, by using Begg's adjusted rank correlation test and Egger's regression asymmetry test. Statistical tests were 2-sided and used a significance level of p < 0.05.
RESULTS
We initially retrieved 1,559 unique citations, elimi- Table 1 ). In studies reporting baseline patient characteristics, mean age, proportion of women, comorbid condition, and medication use were not systematically different between patients taking and not taking macrolides (Online Table 2 ).
Of the 14 observational studies, the scores of the Newcastle-Ottawa quality assessment scale quality assessment ranged from 5 to 9, and 11 studies had scores of 7 or higher. RCT methodological quality was generally good, with modified Jadad score of 4 or higher in 18 studies (Online Tables 3 to 5 Relative risks (RR) of sudden cardiac death (SCD) or ventricular tachyarrhythmia (VTA), cardiovascular death and death from any cause associated with macrolides were compared to no macrolide use. The size of each square is proportional to the study's weight (inverse of variance). Dotted line in the forest plot represents random effects summary risk estimate. CI ¼ confidence interval.
Cheng et al.
Macrolides and Cardiovascular Risk
former use (p ¼ 0.03). A further stratified analysis showed that increased risk of SCD or VTA was observed in users of azithromycin, clarithromycin, and erythromycin, but not roxithromycin ( Table 2) .
In a sensitivity analysis of patients currently taking penicillin or amoxicillin versus those who took no antibiotics, there was no association with increased SCD risk (RR: 0.99; 95% CI: 0.62 to 1.58; p ¼ 0.96).
However, relative to penicillin or amoxicillin, macrolides were associated with an increased risk of SCD or VTA (RR: 1.69; 95% CI: 1.27 to 2.25; p < 0.001) (Online Figure 3) . were not validated in 1 study (Online Table 6 ). Figure 2) .
In stratified analyses, there was no significant heterogeneity by study design, number of events, Relative risks (RR) of mortality and cardiovascular events. CI ¼ confidence interval; SCD ¼ sudden cardiac death; VTA ¼ ventricular tachyarrhythmia. Cheng et al. *Compared with no macrolide use. †p values test homogeneity between strata. ‡Defined according to days of supply from the day the prescription was filled. §Defined as some use of a study medication that was not current but had occurred within the previous 365 days. kAdjusted for age, sex, and cardiovascular risk factors.
CHD ¼ coronary heart disease; RCT ¼ randomized controlled trial; other abbreviations are as in Table 1 . 
RR (95% CI)
Overall, random-effects
Relative risks (RR) of myocardial infarction, stroke, and any cardiovascular events associated with macrolides were compared to no macrolide use. The size of each square is proportional to the study's weight (inverse of variance). Dotted line in the forest plot represents random-effects summary risk estimate.
CI ¼ confidence interval.
heterogeneity (I 2 : 0%; 95% CI: 0% to 84.69%; p ¼ 0.51) (Online Figure 7) .
The average all-cause death rate in patients not Additionally, the absence of an association between roxithromycin and CV risk in our study shows roxithromycin's relative cardiac safety.
STUDY LIMITATIONS. Strengths of this meta-analysis include the strict inclusion criteria, the large number of patients analyzed, the diversity of the study population, and the fact that all subgroup analyses were pre-specified. The absence of important publication bias supports the robustness of the study findings.
Still, there were some study limitations. Fourth, like all meta-analyses, our study has the limitation of being a retrospective analysis; thus, further large RCTs are warranted to confirm these findings.
CONCLUSIONS
Results of this meta-analysis suggest that macrolides may be associated with significant increased risk for SCD or VTA and cardiovascular death but not all-cause mortality. The observed association with increased CV risk seemed to be largely attributed to current use of macrolides. This calls for large welldesigned RCTs to further elucidate the CV safety of macrolides. Lack of significant difference in all-cause death between users of macrolides and no macrolides provide reassurance to clinicians that administration of macrolide antibiotics might be generally safe.
